540,457 Shares in Kenvue Inc. $KVUE Bought by Public Employees Retirement System of Ohio

Public Employees Retirement System of Ohio purchased a new stake in Kenvue Inc. (NYSE:KVUE) in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 540,457 shares of the company’s stock, valued at approximately $10,328,000.

A number of other hedge funds have also recently bought and sold shares of the stock. Johnson Financial Group Inc. acquired a new position in shares of Kenvue during the second quarter valued at about $26,000. CoreCap Advisors LLC lifted its stake in shares of Kenvue by 64.9% in the second quarter. CoreCap Advisors LLC now owns 1,502 shares of the company’s stock valued at $29,000 after buying an additional 591 shares during the period. Elyxium Wealth LLC acquired a new stake in Kenvue during the fourth quarter worth about $26,000. MV Capital Management Inc. acquired a new stake in Kenvue during the fourth quarter worth about $28,000. Finally, Bell Investment Advisors Inc bought a new position in Kenvue during the second quarter valued at about $35,000. 97.64% of the stock is owned by institutional investors.

Kenvue Stock Down 1.4%

Shares of KVUE opened at $18.90 on Tuesday. The company has a quick ratio of 0.71, a current ratio of 1.01 and a debt-to-equity ratio of 0.67. The company has a 50-day moving average price of $19.18 and a two-hundred day moving average price of $18.25. The stock has a market cap of $36.30 billion, a price-to-earnings ratio of 21.72, a P/E/G ratio of 1.37 and a beta of 0.47. Kenvue Inc. has a 12 month low of $14.02 and a 12 month high of $20.82.

Kenvue (NYSE:KVUE) last released its quarterly earnings data on Thursday, August 6th. The company reported $0.31 earnings per share for the quarter, missing the consensus estimate of $0.32 by ($0.01). The company had revenue of $3.96 billion during the quarter, compared to the consensus estimate of $3.97 billion. Kenvue had a net margin of 10.76% and a return on equity of 21.22%. The company’s revenue for the quarter was up 3.0% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.29 earnings per share. Equities analysts predict that Kenvue Inc. will post 1.14 EPS for the current fiscal year.

Kenvue Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, August 26th. Shareholders of record on Wednesday, August 12th were paid a dividend of $0.21 per share. This is an increase from Kenvue’s previous quarterly dividend of $0.21. This represents a $0.84 annualized dividend and a yield of 4.4%. The ex-dividend date was Wednesday, August 12th. Kenvue’s dividend payout ratio is currently 96.55%.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on the company. Barclays upped their price target on Kenvue from $18.00 to $19.00 and gave the company an “equal weight” rating in a report on Tuesday, July 21st. Zacks Research cut Kenvue from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, July 7th. Wall Street Zen lowered Kenvue from a “buy” rating to a “hold” rating in a research note on Saturday, August 8th. UBS Group reduced their target price on Kenvue from $20.00 to $19.00 and set a “neutral” rating for the company in a research report on Tuesday, August 11th. Finally, Weiss Ratings upgraded shares of Kenvue from a “hold (c-)” rating to a “hold (c)” rating in a research note on Monday, June 15th. Three investment analysts have rated the stock with a Buy rating and twelve have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $19.27.

About Kenvue

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.